Tom Willis active positions
| Companies | Position | Start | End |
|---|---|---|---|
SonoThera, Inc.
 SonoThera, Inc. Pharmaceuticals: OtherHealth Technology SonoThera, Inc. is a biotechnology company founded by Michael H. Davidson, Kenneth P. Greenberg, and Steve Feinstein. The company is based in South San Francisco, CA. The company is dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. Kenneth P. Greenberg has been the CEO since incorporation. | Director/Board Member | - | - |
Career history of Tom Willis
Former positions of Tom Willis
| Companies | Position | Start | End |
|---|---|---|---|
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Director/Board Member | - | 2018-12-31 |
Statistics
International
| United States | 3 |
Operational
| Director/Board Member | 2 |
Sectoral
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Health Technology |
| Private companies | 1 |
|---|---|
SonoThera, Inc.
SonoThera, Inc. Pharmaceuticals: OtherHealth Technology SonoThera, Inc. is a biotechnology company founded by Michael H. Davidson, Kenneth P. Greenberg, and Steve Feinstein. The company is based in South San Francisco, CA. The company is dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. Kenneth P. Greenberg has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Tom Willis
- Experience
